PEX16

Across TCGA pan-cancer cohorts, PEX16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PEX16 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PEX16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PEX16 expression acts as an unfavorable survival marker.

BLCA, PAAD, and COAD are the cancer types where PEX16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.183	0.720	.001	27	view →
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	15	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PEX16–BLCA (OS)

Open the BLCA breakdown →